Sandoz has partnered with Chinese biopharmaceutical firm Gan & Lee to market insulin biosimilars that are currently in early and clinical stages of development in the European Union (EU), the US and other key territories.
The commercialization and sales agreement aims to bring to market biosimilar versions of glargine, lispro and aspart forms of insulin,...






